Reviva Pharmaceuticals (NASDAQ:RVPH) Given Speculative Buy Rating at Benchmark

Benchmark reaffirmed their speculative buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a report released on Tuesday, Benzinga reports. They currently have a $17.00 price objective on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $20.00 price target on shares of Reviva Pharmaceuticals in a research report on Monday, March 25th.

Reviva Pharmaceuticals Stock Down 4.3 %

Shares of RVPH stock opened at $3.33 on Tuesday. The stock’s fifty day simple moving average is $3.73 and its 200 day simple moving average is $4.18. Reviva Pharmaceuticals has a twelve month low of $2.67 and a twelve month high of $9.25. The firm has a market capitalization of $92.97 million, a P/E ratio of -1.99 and a beta of -0.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its stake in shares of Reviva Pharmaceuticals by 4,550.0% in the 2nd quarter. Wells Fargo & Company MN now owns 5,115 shares of the company’s stock valued at $30,000 after purchasing an additional 5,005 shares during the period. Tower Research Capital LLC TRC raised its stake in Reviva Pharmaceuticals by 631.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,109 shares of the company’s stock worth $65,000 after buying an additional 9,590 shares during the period. Charles Schwab Investment Management Inc. acquired a new position in Reviva Pharmaceuticals during the 4th quarter worth approximately $52,000. Renaissance Technologies LLC acquired a new position in Reviva Pharmaceuticals during the 1st quarter worth approximately $31,000. Finally, Raymond James & Associates acquired a new position in Reviva Pharmaceuticals during the 1st quarter worth approximately $34,000. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.